BioAegis Therapeutics, Inc.

Our CEO, Susan Levinson, with be a panelist at the 7th Annual Symposium for Life Science Innovation and Development, where she will share BioAegis' progress and our journey at the NJ BioScience Center. #LifeSciences #Innovation #BioAegis #biotech #biotechfunding #savinglives #NewJersey #NJstrong BioNJ New Jersey Economic Development Authority (NJEDA)

A sad loss of a kind man, so generous of his time in pursuing science for patients.

Our team at #BioAegis is saddened to hear of Dr. Gallin's passing.?He was a passionate researcher seeking solutions for patients and we were privileged to collaborate with him and his colleagues on studies in Covid-19 and chronic granulomatous disease (CGD). Deepest condolences from the BioAegis family to his.

Major Milestone – 1st?Patient enrolled in our clinical study. Our $20M contract with?Biomedical Advanced Research and Development Authority (#BARDA)?Division of?Research,?Innovation, and?Ventures (DRIVe) supports the execution of?this major phase 2b global?study of recombinant?human?plasma?#gelsolin (rhu-pGSN)?for?moderate-to-severe?ARDS. The study is being conducted at 75 sites in 13 countries. Enrollment is targeted at 600 patients. ARDS affects over 500,000 patients in the US per year or roughly 10% of all ICU admissions. The mortality rate for ARDS is approximately 40%, yet there are no approved medications for it.? #Gelsolin, a naturally occurring #immunesystem protein, is a master regulator #inflammation. It is depleted by counteracting the inflammatory process. Supplementation with the recombinant gelsolin protein (rhu-pGSN) holds promise to address the inflammatory response associated with ARDS. Susan Levinson Valerie Ceva Steven Cordovano ARDS Alliance #BioAegis, #immunotherapy #NLRP3inflammasome?#immunesystem #hostdirected #clinicaltrials, #lungs, #lungdamage??#respiratoryfailure #savinglives

Announcing four US clinical tial sites are now live! BioAegis is conducting a 600 patient Phase 2b global?study of recombinant human?plasma?gelsolin (rhu-pGSN)?for?moderate-to-severe?Acute Respiratory Distress Syndrome (ARDS) ARDS affects over 500,000 patients in the US per year or roughly 10% of all ICU admissions. The mortality rate for ARDS is approximately 40%. The lack of effective therapies to treat ARDS and its associated high mortality driven by excess #inflammation underscores the urgent need for an innovative therapy in this field. #Gelsolin, a naturally occurring #immunesystem protein, is a master regulator inflammation. It is depleted by counteracting the inflammatory process. Supplementation with the recombinant gelsolin protein (rhu-pGSN) holds promise to address the inflammatory response associated with ARDS. "ARDS is significant source of mortality as well as a drain on healthcare resources across the globe. We are committed to reaching our goal of saving lives by addressing the challenges of this complex disease,"?stated?Susan Levinson, Ph.D., Chief Executive Officer of BioAegis. #gelsolin, #ARDS, #clinicaltrials, #lungs, #lungdamage???#respiratoryfailure #savinglives #sepsis #pneumonia #covid19

21,156 vials ready for our clinical trial! #BioAegis is conducting a major global Phase 2 study of #gelsolin for the treatment of patients with moderate to severe Acute Respiratory Distress Syndrome (#ARDS). Enrollment is targeted at 600 patients in 13 counties. ARDS, a life threatening lung condition, has a 40% mortality rate, yet there are NO approved medications for this deadly condition. Our lead product, #rhu-pGSN, is the recombinant form of plasma gelsolin, a naturally occurring #immunesystem protein and master regulator of inflammation. Gelsolin is depleted in the body when counteracting the inflammatory process. Supplementation with the recombinant gelsolin protein (rhu-pGSN) holds much promise to address the extreme inflammatory response associated with ARDS. #BioAegis, #gelsolin, #ARDS, #clinicaltrials, #lungs, #lungdamage???#respiratoryfailure #savinglives

?? Today is World Lung Day -- A day to raise awareness about the critical importance of lung health. At #BioAegis, we are proud to be contributing to this mission through innovative research and development. Our on-going global Phase 2 study is focused on advancing the treatment of recombinant human #gelsolin (rhu-pGSN) for patients with moderate to severe Acute Respiratory Distress Syndrome (#ARDS). #worldlungday #savinglives #lunghealth #lungdisease #clinicalstudies #immunotherapy #immunesystem

#BioAegis Co-founder, Steven Cordovano, will present at the MedInvest Biotech & Pharma Investor Conference in New York City this week. The presentation,?“Conquering Diseases Driven by Excess Inflammation,”?will highlight BioAegis’ novel, #hostdirected treatment, recombinant plasma #gelsolin (rhu-pGSN). It will also discuss BioAegis’ lead indication, Acute Respiratory Distress Syndrome (#ARDS), and its recently initiated Phase 2 global study. The presentation will take place on Thursday, September 19th at 10:25AM. To watch live, please register, https://lnkd.in/eN9amY7g #biotech #immunotherapy #savinglives #medinvest

Thank you to the ARDS Alliance for their dedication to raising awareness and improving the quality of life for people affected by Acute Respiratory Distress Syndrome (ARDS). "ARDS is significant source of mortality as well as a drain on healthcare resources across the globe. We are committed to reaching our goal of saving lives by addressing the challenges of this complex disease," stated Susan Levinson, Ph.D., Chief Executive Officer of BioAegis. BioAegis is conducting a global Phase 2 study of recombinant human #gelsolin (rhu-pGSN) for the treatment of patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS). #BARDA #ardsawarenessday #immunesystem #lungdamage #clinicaltrials #lunghealth #lungs

Celebrating ARDS Awareness Day. #ARDS is a very serious condition. It affects over 500,000 patients in the US per year or roughly 10% of all ICU admissions. The mortality rate is approx. 40%. The lack of effective therapies to treat ARDS and its high mortality driven by excess #inflammation underscores the urgent need for an innovative therapy in this field. #BioAegis is conducting a global phase2 trial of recombinant human #gelsolin (rhu-pGSN) for the treatment of ARDS. ARDS Alliance #savinglives #ardsalliance #ARDS #clinicaltrials #savinglives #pneumonia #sepsis #immunotherapy #biotechinvesting #NLR3Pinflammasome #lungdamage